



**PEER-REVIEW REPORT**

**Name of journal:** World Journal of Clinical Cases

**Manuscript NO:** 39503

**Title:** PNPLA3 rs738409 underlies treatment response in nonalcoholic fatty liver disease

**Reviewer’s code:** 00053423

**Reviewer’s country:** Brazil

**Science editor:** Jin-Lei Wang

**Date sent for review:** 2018-04-24

**Date reviewed:** 2018-05-01

**Review time:** 7 Days

SCIENTIFIC QUALITY	LANGUAGE QUALITY	CONCLUSION	PEER-REVIEWER STATEMENTS
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	<input type="checkbox"/> Accept	Peer-Review:
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language	(High priority)	<input type="checkbox"/> Anonymous
<input type="checkbox"/> Grade C: Good	polishing	<input type="checkbox"/> Accept	<input type="checkbox"/> Onymous
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of	(General priority)	Peer-reviewer’s expertise on the
<input type="checkbox"/> Grade E: Do not	language polishing	<input type="checkbox"/> Minor revision	topic of the manuscript:
publish	<input type="checkbox"/> Grade D: Rejection	<input type="checkbox"/> Major revision	<input type="checkbox"/> Advanced
		<input type="checkbox"/> Rejection	<input type="checkbox"/> General
			<input type="checkbox"/> No expertise
			Conflicts-of-Interest:
			<input type="checkbox"/> Yes
			<input type="checkbox"/> No

**SPECIFIC COMMENTS TO AUTHORS**

The study of Wang et al is a well performed review reporting studies that support a possible role in PNPLA3 polymorphisms as determinants of response to treatment options of NAFLD. I have a suggestion to improve the quality of the manuscript However, I think that for complex diseases like NAFLD, the effect of any genetic risk



**Baishideng  
Publishing  
Group**

7901 Stoneridge Drive, Suite 501,  
Pleasanton, CA 94588, USA  
**Telephone:** +1-925-223-8242  
**Fax:** +1-925-223-8243  
**E-mail:** bpgoffice@wjgnet.com  
**https://**www.wjgnet.com

variant is unlikely to be sufficient to be clinically meaningful , nonetheless the identified NAFLD risk loci do provide hope for the development of risk algorithms for improved patient stratification and management. Maybe the authors should also address this aspect , the I148 PNPLA3 is one of the genetic variant most associated with NAFLD , but not the only one .

#### **INITIAL REVIEW OF THE MANUSCRIPT**

##### ***Google Search:***

- The same title
- Duplicate publication
- Plagiarism
- No

##### ***BPG Search:***

- The same title
- Duplicate publication
- Plagiarism
- No